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bstract Background: The low-grade inflammatory condition present in morbid obesity is thought to play a
causative role in the pathophysiology of insulin resistance (IR). Bariatric surgery fails to improve this
inflammatory condition during the first months after surgery. Considering the close relation between
inflammation and IR, we conducted a study in which insulin sensitivity was measured during the first
months after bariatric surgery. Different methods to measure IR shortly after bariatric surgery have given
inconsistent data. For example, the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
levels have been reported to decrease rapidly after bariatric surgery, although clamp techniques have
shown sustained insulin resistance. In the present study, we evaluated the use of steady-state plasma
glucose (SSPG) levels to assess insulin sensitivity 2 months after bariatric surgery.
Methods: Insulin sensitivity was measured using HOMA-IR and SSPG levels in 11 subjects before
surgery and at 26% excess weight loss (approximately 2 months after restrictive bariatric surgery).
Results: The SSPG levels after 26% excess weight loss did not differ from the SSPG levels before
surgery (14.3  5.4 versus 14.4  2.7 mmol/L). In contrast, the HOMA-IR values had decreased
significantly (3.59  1.99 versus 2.09  1.02).
Conclusion: During the first months after restrictive bariatric surgery, we observed a discrepancy
between the HOMA-IR and SSPG levels. In contrast to the HOMA-IR values, the SSPG levels had
not improved, which could be explained by the ongoing inflammatory state after bariatric surgery.
These results suggest that during the first months after restrictive bariatric surgery, HOMA-IR might
not be an adequate marker of insulin sensitivity. (Surg Obes Relat Dis 2010;6:340–346.) © 2010
American Society for Metabolic and Bariatric Surgery. All rights reserved.








Bariatric surgery is considered to be the best treatment of
orbid obesity and its co-morbidities [1]. In the long term,
ariatric surgery not only results in improved body weight,
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550-7289/10/$ – see front matter © 2010 American Society for Metabolic and B
oi:10.1016/j.soard.2009.11.011ut also reduces the low-grade inflammatory condition as-
ociated with morbid obesity [2]. Extensive evidence has
hown that this low-grade inflammatory condition plays a
ausative role in the pathophysiology of insulin resistance
IR) [3–7]. For example, treatment of subjects with IR
sing the anti-inflammatory drug acetylsalicylic acid re-
ulted in improved insulin sensitivity [8,9]. In addition,
revious studies have shown increased insulin sensitivity
































































































341F. M. H. van Dielen et al. / Surgery for Obesity and Related Diseases 6 (2010) 340–346nd reduced inflammation in the long term after bariatric
urgery [10,11].
However, previous data have shown that despite substan-
ial weight loss, several parameters of the low-grade inflam-
atory condition did not decrease during the first months
fter bariatric surgery. The plasma levels of acute phase
roteins and the tumor necrosis factor (TNF)- receptor, as
ell as markers of endothelial activation and adiponectin
nd resistin levels, remained unchanged at 3 months after
urgery [10,12]. Therefore, IR is not expected to decline
uring the first months after bariatric surgery.
Insulin sensitivity can be measured using clamp tech-
iques, intravenous or oral glucose tolerance tests, and val-
dated models such as the Homeostatic Model Assessment
f Insulin Resistance (HOMA-IR) and Quantitative Insulin
ensitivity Check Index. The euglycemic hyperinsulinemic
lamp technique is the reference standard, but other tech-
iques such as the steady state plasma glucose (SSPG) test
ave been developed that are less likely to result in hypo-
lycemia. Measuring the SSPG levels is a well-validated
lternative introduced by Shen et al. [13] and Reaven and
lefsky [14]. It is a method that has been used for 35
ears to measure insulin sensitivity and correlates strongly
r .90) with the more commonly used euglycemic hyper-
nsulinemic clamp technique. The SSPG test is an insulin
uppression test that determines a steady state of plasma
lucose concentration as a measure for insulin-mediated
lucose uptake [13,14].
Many studies have shown that the HOMA-IR values
ecrease in the first months after bariatric surgery [15–17].
owever, studies using the clamp techniques directly after
ariatric surgery have been limited and inconsistent, show-
ng both decreased IR and no change in IR [18,19]. This led
s to investigate insulin sensitivity before and approxi-
ately 2 months after bariatric surgery, when patients had
ost 26% of their excess weight, using both the HOMA-IR
nd SSPG levels.
ethods
A total of 11 consecutive patients who were admitted to
he surgical department of the University Hospital Maas-
richt for restrictive surgical treatment of morbid obesity
articipated in the present study. Of the 11 patients, 7
nderwent vertical banded gastroplasty and 4 underwent
apBand surgery. The patients were otherwise healthy ac-
ording to their history, clinical examination, and routine
aboratory test findings. In particular, none of the studied
atients had evidence of diabetes mellitus or inflammatory
isease or were taking medications known to influence the
lucose metabolism or inflammation. The morbidly obese
atients underwent the SSPG test before gastric restrictive
urgery (baseline) and after 26% excess weight loss (EWL).
uring the 2-month period, no significant band adjustments
ere performed in the LapBand patients. The characteristics af the study population are presented in Table 1. The ethical
ommittee of the University Hospital Maastricht (Maas-
richt, The Netherlands) approved the study. All patients
ave written informed consent.
SPG test and HOMA-IR
Insulin sensitivity was studied by determining the SSPG
evels. First, the endogenous insulin production by the pan-
reas was suppressed using octreotide (Sandostatin, Novar-
is Pharma B.V., Arnhem, The Netherlands), given as bolus
ollowed by a continuous infusion. Next, glucose and insu-
in were infused at a fixed rate. At 150–180 minutes, the
lasma insulin and glucose levels had reached a steady state.
hese levels are termed the steady state plasma insulin
SSPI) and SSPG levels. The SSPG level is a reflection of
nsulin-mediated glucose uptake and a marker of insulin
ensitivity. Thus, it is essential for the preoperative SSPI
evels to be comparable to the SSPI levels at 26% EWL.
After a 12-hour overnight fast, the body weight and body
eight were measured. The patients were measured in the
upine position in a hospital bed. Catheters were placed in
oth antecubital veins to enable infusion of glucose, insulin,
nd octreotide, as well as venous blood sampling. During an
cclimatization period of 30 minutes, an automatic blood
ressure measurement (Dinamap, Criticon, Tampa, FL) was
aken. Octreotide, a somatostatin analogue, was adminis-
ered intravenously using a syringe infusion pump (Treonic
P4, Vickers Medical, Sidcap Kent, England) at 5.0 g/min,
receded by a bolus of 25 g. In both the pre- and postop-
rative measurements of SSPG, the same octreotide concen-
ration was used, decreasing the chance of confounding the
esults from high octreotide plasma concentrations. Insulin
Actrapid, Novo-Nordisk, Bagsærd, Denmark) was infused
t a rate of 25 mU/m2/min using a second syringe pump.
lucose was infused using a volumetric pump (IVAC 591,
VAC, San Diego, CA) at 240 mU/m2/min. Before the test
able 1








ge (yr) 40.4  7.6 40.4  7.6
ody mass index (kg/m2) 44.6  3.3 39.4  3.4*
aist/hip ratio 0.97  0.08 0.93  0.1
eight loss (kg) 14.9  3.3
asting glucose (mmol/L) 5.4  0.6 5.5  0.7
asting insulin (mU/L) 14.8  7.8 7.4  4.5*
OMA-IR 3.59  1.99 2.09  1.02*
ostoperative interval (d) 53  26
EWL  excess weight loss; HOMA-IR  Homeostatic Model Assess-
ent of Insulin Resistance.







































































342 F. M. H. van Dielen et al. / Surgery for Obesity and Related Diseases 6 (2010) 340–346ere taken. The mean plasma glucose level at 150, 160,
70, and 180 minutes was defined as the SSPG level. The
SPG levels provide an indirect measure of IR [20].
Plasma glucose was determined using a glucose oxidase
ethod (YSI model 2300 Stat, Yellow Springs Industries,
ellow Springs, OH). The blood samples for determining
he inflammatory mediators and insulin were immediately
ut on melting ice, and the plasma was prepared by centrif-
gation at 1400g for 10 minutes at 4°C. The plasma was
entrifuged again at 2700g for 10 minutes at 4°C, and the
ecovered plasma was stored in aliquots at 80°C until
easurement.
HOMA-IR is a mathematical model by which insulin
ensitivity can be assessed using the fasting glucose and
nsulin plasma levels [21].
eagents, materials, and assays
The plasma concentrations of soluble TNF- receptors,
eptin, lipopolysaccharide-binding protein, C-reactive pro-
ein, 1-acid glycoprotein, and insulin were measured
sing sandwich enzyme-linked immunosorbent assays.
he TNF- receptors (55 and 75), leptin, lipopolysaccha-
ide-binding protein, C-reactive protein, and 1-acid glyco-
rotein were measured, as described previously [10]. The
lasma insulin concentrations were measured using a com-
ercially available enzyme-linked immunosorbent assay
Mercodia AB, Uppsala, Sweden).
All plasma samples were measured in the same run,
xcept for the plasma insulin concentrations. When the
lasma concentrations exceeded the upper detection limit of
he assay, the samples were diluted more and analyzed in a
eparate run with an overlap. The intra- and interassay
oefficients of variance of the assays were 10%.
tatistical analysis
The data are expressed as the mean  standard deviation.
he Wilcoxon sign-rank test was used to analyze the dif-
erences. P .05 was considered statistically significant.
esults
ffect of weight loss on metabolic and
nflammatory mediators
After bariatric surgery, 26%  4% EWL was reached
ithin 53  26 days, resulting in a body mass index de-
rease from 46.2  5.6 kg/m2 (preoperatively) to 40.7  4.1
g/m2 postoperatively. The mean percentage weight loss
as 11.6%  1.6% for the study subjects.
As listed in Table 1, the fasting plasma glucose levels
efore surgery were in the normal range (5.6 mmol/L),
ith increased fasting plasma insulin levels (14.8  7.8
U/L; normal 12 mU/L ) resulting in an increased
OMA-IR (3.59  1.99). The fasting plasma glucose levelst 26% EWL were similar to the preoperative values. In tontrast, the fasting insulin plasma levels and HOMA-IR
ecreased after surgery (7.4  4.5 mU/L and 2.09  1.02,
espectively; P .05).
Fig. 1 shows the pre- and postoperative SSPI and SSPG
evels. Because the SSPI levels were not significantly dif-
erent pre- and postoperatively (P  .76), the pre- and
ostoperative SSPG levels could be compared. Preopera-
ively, the glucose levels were increased during the SSPG
est to reach an SSPG concentration of 14.4  2.7 mmol/L.
his concentration was much greater than the SSPG levels
ound in healthy subjects (4.1  0.4 mmol/L), indicating
educed preoperative insulin sensitivity in our morbidly
bese subjects. These data represent the lower 30th percen-
ile of IR as measured by Yeni-Komshian et al. [22] in 490
ealthy volunteers.
The mean SSPG concentration before surgery was not
ignificantly different from the mean SSPG concentration
fter bariatric surgery at 26% EWL (14.3  5.3 mmol/L),
uggesting sustained IR.
Because inflammation is known to contribute to IR, we
lso investigated the plasma levels of inflammatory mole-
ules before and after surgery. In line with earlier data [10],
he plasma leptin levels had decreased significantly, but the
irculating levels of acute phase proteins (C-reactive pro-
ig. 1. Pre- and postoperative SSPI and SSPG levels. (A) Preoperative
SPI values did not significantly differ from those measured at 26% EWL
14.4  2.7 versus 14.3  5.4 mmol/L). Therefore, pre- and postoperative
SPG levels could be compared. (B) SSPG levels did not decrease in first
onths after restrictive bariatric surgery, indicating that during the first




































































































343F. M. H. van Dielen et al. / Surgery for Obesity and Related Diseases 6 (2010) 340–346rotein) and TNF- receptors had not changed, despite the
ubstantial weight loss at 26% EWL (Table 2). A separate
nalysis of the LapBand and vertical banded gastroplasty
tudy subjects did not show differences in outcome.
iscussion
Considering the close relationship between inflammation
nd IR, the insulin sensitivity was measured during the first
onths after surgery, which is characterized by ongoing
nflammation. Previous data published by our group have
ndicated that in the long term after bariatric surgery (3
ears postoperatively, 70% EWL), the SSPG levels improve
23]. However, the results of the present study have shown
hat the SSPG levels had not decreased at 2 months after
urgery, indicating that the patients still experienced IR
espite their substantial weight loss. Similar results were
btained in a study using the euglycemic hyperinsulinemic
lamp technique to measure insulin sensitivity after gastric
ypass surgery and biliopancreatic diversion (BPD) [18].
pproximately 5 months postoperatively, the IR had not
ecreased in the gastric bypass group. In contrast, insulin
ensitivity had significantly improved at 5 months after
PD. Insulin sensitivity will have already been ameliorated
ithin 4 weeks after BPD [19]. Because gastric bypass
urgery is considered restrictive, with only a minor malab-
orptive component [24], the results of the present study
upport the concept that techniques mainly using restriction,
nlike malabsorptive procedures, do not immediately re-
uce peripheral insulin sensitivity. It is thought that incre-
ins such as glucagon-like peptide-1 (GLP-1) and gastroin-
estinal polypeptide play a central role in the observed
ifferences [19]. Malabsorptive surgery results in bypass of
he foregut, as well as exposure of the distal ileum to
ndigested food. Consequently, the secretion of gastrointes-
inal polypeptide and GLP-1 is altered [25]. Both gastroin-
estinal polypeptide and GLP-1 are known to increase insu-
in sensitivity and secretion [26]; therefore, malabsorptive
urgery is thought to be more effective in increasing insulin
able 2





eptin (ng/mL) 67.0  31.5 26.9  14.3*
RP (g/mL) 20.3  12.1 21.9  17.1
GP (ng/mL) 12.1  7.7 10.3  5.2
BP (g/mL) 36.2  16.9 35.1  11.6
oluble TNFR55 (ng/mL) 0.6  0.21 0.67  0.2
oluble TNFR75 (ng/mL) 1.07  0.43 1.34  0.47
SSPG  steady-state plasma glucose; EWL  excess weight loss;
RP  C-reactive protein; AGP  1-acid glycoprotein; LBP  lipopo-
ysaccharide-binding protein; TNF  tumor-necrosis factor.
* P .05 compared with preoperatively.ensitivity than purely restrictive procedures. This has been allustrated by Laferrere et al. [27], who compared the oral
lucose tolerance after gastric bypass surgery to the glucose
olerance after a 1 month of a very low calorie diet. Gastric
ypass resulted in lower postprandial glucose levels, despite
omparable weight loss. This difference could be explained
y the greater levels of GLP-1 after gastric bypass surgery.
A possible explanation for the unchanged SSPG levels in
he first months after bariatric surgery, such as were ob-
erved in the present study, could be insufficient weight
oss. At 26% EWL, the subjects had lost approximately 15
g, but the body mass index remained in the morbid obese
pectrum (39.4 kg/m2). Thus, it appears that peripheral
nsulin sensitivity only starts to improve after a certain set
oint, which was not reached in our study population. How-
ver, studies of obese individuals restricted to a very low
alorie diet have shown increased insulin sensitivity using
lamp techniques. These subjects lost a significant amount
f weight, although not as much as our study population. An
xplanation for this effect could be that the major surgical
rocedure influences insulin sensitivity, for example, by
rovoking other inflammatory processes. In line with pre-
ious studies from our group, the inflammatory condition
id not improve during the first 2 months after bariatric
urgery in the present study [10,12]. Another explanation
elates to the severe catabolic state associated with substan-
ial weight loss in the first months after bariatric surgery.
hus, several studies have shown decreased insulin sensi-
ivity in adipose tissue during fasting [28,29]. The incon-
istency of restrictive versus malabsorptive bariatric proce-
ures with respect to their early effects on insulin sensitivity
hould be the subject of future research.
In contrast to the unchanged insulin sensitivity as mea-
ured by SSPG testing in the first months after surgery, the
OMA-IR levels had decreased significantly at that point.
his was mainly because of reduced fasting plasma insulin
evels after surgery, although the circulating fasting plasma
lucose levels had not changed significantly during the
-month period. These results indicate that during the first
onths after bariatric surgery, the HOMA-IR index might
ot be valid as a marker of insulin sensitivity.
The observed differences between HOMA-IR and SSPG
ight be explained by the storage capacity of the liver for
acronutrients. In insulin-resistant morbidly obese patients
ithout type 2 diabetes, increased fasting plasma insulin
evels and normal or slightly increased fasting plasma glu-
ose levels will be found. This is thought to be related to the
ncreased gluconeogenesis during the fasting period in in-
ulin-resistant hepatocytes and results in elevated insulin
roduction by the pancreas [30]. We suggest that during
apid weight loss, the hepatocytes might lose the stored
acronutrients earlier than do the skeletal muscle cells or
dipocytes, leading to increased hepatic insulin sensitivity
ompared to the skeletal muscle or adipocytes, resulting in
educed fasting plasma insulin levels. Perhaps this could












































344 F. M. H. van Dielen et al. / Surgery for Obesity and Related Diseases 6 (2010) 340–346ypass with respect to the improvement of insulin sensitiv-
ty postoperatively. The more rigorous weight loss occur-
ing after BPD could force triglycerides out of the muscle
nd adipose tissue more rapidly compared with other types
f bariatric surgery. The SSPI levels did not decrease, in-
icating that the insulin clearance capacity of the liver was
till impaired and, thus, not paralleling the decline in glu-
oneogenesis. Unpublished data from our group have indi-
ated decreased SSPI levels at 50% EWL, demonstrating
ncreased insulin clearance by the liver.
onclusion
In the present small study of nondiabetic, insulin-resistant
atients, we found that IR as measured by SSPG did not
mprove, despite substantial weight loss, in the first months
fter restrictive bariatric surgery, paralleling the sustained low-
rade inflammatory condition. In contrast, the HOMA-IR val-
es decreased during the first months after restrictive bariatric
urgery, suggesting that the HOMA-IR index is not an ade-
uate marker of insulin sensitivity after restrictive bariatric
urgery.
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